FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894943986> ?p ?o ?g. }

• W2894943986 abstract "Chemotherapy-induced oral mucositis impairs the quality of life. The difference in severity of oral mucositis between different anti-epidermal growth factor receptor (EGFR) antibodies combined with cytotoxic drugs in colorectal cancer is unclear. The aim of this study was to investigate the differences in oral mucositis between panitumumab (Pmab) and cetuximab (Cmab) combined with 5-fluorouracil (5-FU).We conducted a retrospective cohort study. A total of 75 colorectal cancer outpatients treated with an anti-EGFR antibody combined with FOLFOX, FOLFIRI, or 5-FU/leucovorin as the first- to third-line treatment were included. The primary endpoint was the incidence of grade 2-3 oral mucositis. The secondary endpoint was the time to onset of oral mucositis. We also compared the incidence of toxicities of interest, skin toxicity, hypomagnesaemia and neutropenia, and time to treatment failure (TTF) between the two groups.Thirty-two patients treated with Pmab and 43 patients treated with Cmab were evaluated. Patient characteristics were similar between the two groups. The incidence of grade 2-3 oral mucositis was significantly higher with Pmab than with Cmab (31.3% vs 9.3%, P < 0.05). Moreover, the incidence of grade 3 oral mucositis was significantly higher in patients treated with Pmab (18.8% vs 0%, P < 0.01). The mean (SD) cycles to onset of the worst oral mucositis was 3.0 (2.9) in the Pmab group and 2.3 (1.7) in the Cmab group (P = 0.29). Oral mucositis was characterized by glossitis and cheilitis. The incidences of other toxicities were the following (Pmab vs Cmab): grade 2-3 skin toxicity: 68.8% vs 74.4% (P = 0.61), grade 2-3 hypomagnesaemia: 9.3% vs 7.0% (P = 1.00), grade 3-4 neutropenia: 28.1% vs 37.2% (P = 0.46). The median TTF was not significantly different, i.e., 223 days vs 200 days (P = 0.39) for Pmab vs Cmab.Pmab-based chemotherapy resulted in significantly higher grades of oral mucositis compared with Cmab-based chemotherapy. The oral condition should be monitored carefully and early supportive care should be provided for patients treated with Pmab-based chemotherapy." @default.
• W2894943986 created "2018-10-12" @default.
• W2894943986 creator A5000863624 @default.
• W2894943986 creator A5010201656 @default.
• W2894943986 creator A5047610881 @default.
• W2894943986 creator A5049258575 @default.
• W2894943986 creator A5055771757 @default.
• W2894943986 creator A5061018209 @default.
• W2894943986 creator A5078901343 @default.
• W2894943986 date "2018-10-05" @default.
• W2894943986 modified "2023-10-18" @default.
• W2894943986 title "Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study" @default.
• W2894943986 cites W1921819744 @default.
• W2894943986 cites W1964216428 @default.
• W2894943986 cites W2000436105 @default.
• W2894943986 cites W2005348280 @default.
• W2894943986 cites W2017064986 @default.
• W2894943986 cites W2024381955 @default.
• W2894943986 cites W2026875965 @default.
• W2894943986 cites W2044738098 @default.
• W2894943986 cites W2050547509 @default.
• W2894943986 cites W2051363346 @default.
• W2894943986 cites W2053772337 @default.
• W2894943986 cites W2074258060 @default.
• W2894943986 cites W2081820230 @default.
• W2894943986 cites W2098354753 @default.
• W2894943986 cites W2099781164 @default.
• W2894943986 cites W2108235590 @default.
• W2894943986 cites W2111321585 @default.
• W2894943986 cites W2117993382 @default.
• W2894943986 cites W2120458151 @default.
• W2894943986 cites W2130017822 @default.
• W2894943986 cites W2131605375 @default.
• W2894943986 cites W2133045939 @default.
• W2894943986 cites W2143536404 @default.
• W2894943986 cites W2145070131 @default.
• W2894943986 cites W2151601248 @default.
• W2894943986 cites W2156670712 @default.
• W2894943986 cites W2158334747 @default.
• W2894943986 cites W2166191933 @default.
• W2894943986 cites W2340196059 @default.
• W2894943986 cites W2341933843 @default.
• W2894943986 cites W2342104842 @default.
• W2894943986 cites W2470575266 @default.
• W2894943986 cites W2555386347 @default.
• W2894943986 cites W302199081 @default.
• W2894943986 cites W3190697283 @default.
• W2894943986 cites W591339985 @default.
• W2894943986 doi "https://doi.org/10.1186/s12885-018-4862-z" @default.
• W2894943986 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6173836" @default.
• W2894943986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30290786" @default.
• W2894943986 hasPublicationYear "2018" @default.
• W2894943986 type Work @default.
• W2894943986 sameAs 2894943986 @default.
• W2894943986 citedByCount "8" @default.
• W2894943986 countsByYear W28949439862019 @default.
• W2894943986 countsByYear W28949439862020 @default.
• W2894943986 countsByYear W28949439862022 @default.
• W2894943986 countsByYear W28949439862023 @default.
• W2894943986 crossrefType "journal-article" @default.
• W2894943986 hasAuthorship W2894943986A5000863624 @default.
• W2894943986 hasAuthorship W2894943986A5010201656 @default.
• W2894943986 hasAuthorship W2894943986A5047610881 @default.
• W2894943986 hasAuthorship W2894943986A5049258575 @default.
• W2894943986 hasAuthorship W2894943986A5055771757 @default.
• W2894943986 hasAuthorship W2894943986A5061018209 @default.
• W2894943986 hasAuthorship W2894943986A5078901343 @default.
• W2894943986 hasBestOaLocation W28949439861 @default.
• W2894943986 hasConcept C120665830 @default.
• W2894943986 hasConcept C121332964 @default.
• W2894943986 hasConcept C121608353 @default.
• W2894943986 hasConcept C126322002 @default.
• W2894943986 hasConcept C143998085 @default.
• W2894943986 hasConcept C167135981 @default.
• W2894943986 hasConcept C203092338 @default.
• W2894943986 hasConcept C2776694085 @default.
• W2894943986 hasConcept C2778496288 @default.
• W2894943986 hasConcept C2779998722 @default.
• W2894943986 hasConcept C526805850 @default.
• W2894943986 hasConcept C535046627 @default.
• W2894943986 hasConcept C61511704 @default.
• W2894943986 hasConcept C71924100 @default.
• W2894943986 hasConcept C90924648 @default.
• W2894943986 hasConceptScore W2894943986C120665830 @default.
• W2894943986 hasConceptScore W2894943986C121332964 @default.
• W2894943986 hasConceptScore W2894943986C121608353 @default.
• W2894943986 hasConceptScore W2894943986C126322002 @default.
• W2894943986 hasConceptScore W2894943986C143998085 @default.
• W2894943986 hasConceptScore W2894943986C167135981 @default.
• W2894943986 hasConceptScore W2894943986C203092338 @default.
• W2894943986 hasConceptScore W2894943986C2776694085 @default.
• W2894943986 hasConceptScore W2894943986C2778496288 @default.
• W2894943986 hasConceptScore W2894943986C2779998722 @default.
• W2894943986 hasConceptScore W2894943986C526805850 @default.
• W2894943986 hasConceptScore W2894943986C535046627 @default.
• W2894943986 hasConceptScore W2894943986C61511704 @default.
• W2894943986 hasConceptScore W2894943986C71924100 @default.
• W2894943986 hasConceptScore W2894943986C90924648 @default.
• W2894943986 hasIssue "1" @default.
• W2894943986 hasLocation W28949439861 @default.

• next